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Anti-hrB and anti-HrB are rare alloantibodies found predominantly in
people of Black African descent. It has been assumed that strongly
reacting examples of anti-hrB may cause hemolytic transfusion
reactions, but precise information is limited. Anti-HrB is a clinically
significant antibody and may cause hemolytic transfusion reactions
and HDN. Selection of blood for transfusion support for patients
with these alloantibodies, and especially with anti-HrB, imposes a
special challenge in the United Kingdom. We report two antenatal
patients (both patients were of the partial D phenotype DIII), one
with anti-hrB, anti-Ce, and anti-D; the other, with anti-hrB and anti-D,
who later formed anti-HrB. Transfusion support and the outcome of
the pregnancies are discussed. A literature search confirms that,apart
from some publications in abstract form, there is not much detailed
clinical information available for either anti-hrB or anti-HrB. Further
information and publications are warranted to gain more knowledge
of these rare antibodies. Immunohematology 2007;23:143–5.
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Patients of BlackAfrican descent with variant RHCE
genes may make alloanti-e-like antibodies such as anti-
hrB.1 There is scant information available regarding the
clinical significance of anti-hrB, but it has been
recommended that hrB– units be provided for potent
anti-hrB.2 Transfusion of hrB– blood is often achieved by
using R2R2 (e–, hrB–) blood. These patients may make
anti-E (if E–), anti-HrB, or both.2,3 This, in turn,may lead
to complications in antibody identification and
provision of suitable blood. Anti-HrB is a clinically
significant antibody against the high-prevalence HrB
(Rh34) antigen and may cause HDN.4 We report two
antenatal patients with the partial D phenotype DIII,one
who made anti-hrB, anti-Ce, and anti-D, the other who
made anti-hrB and anti-D, who later formed anti-HrB.




A 30-year-old woman of African-Caribbean origin
was seen at the antenatal clinic at 19 weeks’ gestation.
This was her second pregnancy. During her previous
pregnancy weakly reacting anti-D, anti-Ce, and anti-hrB
were identified in her serum. The International Blood
Group Reference Laboratory (IBGRL), Bristol, United
Kingdom,confirmed her blood group asA,probable Rh
genotype CceS/DIIIce. Review of the case showed that
there was no evidence of HDN during her previous
pregnancy; the RBCs from her baby’s cord sample were
negative in the DAT, with a Hb of 19 g/dL at delivery.
The patient had not received a blood transfusion. At her
initial antenatal visit for the second pregnancy, only
weakly reacting anti-hrB and anti-D were identified in
her serum. The patient missed her follow-up appoint-
ments, but revisited the clinic at 39 weeks’ gestation.
Serologic investigation showed the presence of weakly
reacting anti-hrB, anti-D, and anti-Ce. Rh phenotype r″r″
(cE/cE) RBCs were reserved to cover the delivery. The
patient delivered a normal,healthy baby by vaginal route
and did not require transfusion. The DAT on the RBCs
from the cord sample was negative and the baby
showed no clinical evidence of HDN.
Patient 2
A 29-year-old woman of West African origin, with
sickle cell anemia (HbSS), was seen at 20 weeks’
gestation. Her sickle cell disease ran a mild course. She
had a history of recurrent miscarriages and had no live
children. She had been transfused previously on two
occasions. Three years previously, at another hospital,
“pan-reacting antibodies” had been identified in her
serum,and the IBGRL confirmed the presence of weakly
reacting anti-D and anti-hrB. Her blood was typed as
groupAB and the probable Rh genotype was reported as
CceS/DIIIce. At presentation in the index pregnancy,
only weakly reacting anti-hrB was detected in the serum.
Although the pregnancy progressed satisfactorily, she
experienced sickle-related pain, leading to short
admissions. Her Hb was stable at approximately 7.0
g/dL, and transfusion was avoided. It was planned to
provide r″r″, K– RBCs should the patient need trans-
fusion support. At 32 weeks’ gestation, unexpectedly,
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anti-HrB was detected in her serum,resulting in the need
for Rhnull or HrB– or units from a donor with the same
unusual blood type. Units of HrB– RBCs would have to
have been imported from SouthAfrica. We were able to
reserve two units of Rhnull RBCs at the National Frozen
Blood Bank (NFBB),United Kingdom,for the patient. At
35 weeks’gestation,the patient experienced acute sickle
chest syndrome. She was treated supportively, and the
infant was delivered by cesarean section under spinal
anesthesia. The two frozen units of Rhnull RBCs were
thawed, and transfused preoperatively and post-
operatively. Her Hb the day after delivery was 7.8 g/dL.
The infant’s RBCs typed as group B, D+. The DAT was
positive (anti-IgG 2+, anti-C3d 1+).The infant’s Hb at
delivery was 15.2 g/dL, with a bilirubin level of 157
µol/L (normal range, 5–180 µol/L). No therapy was
required.
Materials and Methods
Column agglutination technology (DiaMed-AG,
Cressier sur Morat, Switzerland) was used at National
Blood Service (NBS)-Tooting Centre, using standard
serologic methods. To establish whether other clinically
significant alloantibodies were underlying the anti-hrB
or anti-HrB present, multiple differential alloadsorption
studies were undertaken with papain-treated R1R1,R2R2,
and rr RBCs (NBS Reagents,Cambridge,UK).
In the serum of Patient 1, the apparent anti-Ce gave
significantly more avid reactions than did the anti-hrB
(i.e., more avid reactions were detected with RBCs
expressing the Ce haplotype, with or without a ce
haplotype in the trans position, than those expressing
the ce haplotype only, even in presumed homozygous
expression). Samples from both patients were referred
to the IBGRL,which confirmed the presence of anti-hrB,
anti-D,and anti-Ce in the serum of Patient 1 and anti-HrB
in the serum of Patient 2, respectively. Extensive Rh
typing was undertaken by the IBGRL for both patients.
Results
Patient 1
The RBCs of the patient were typed as groupA;M+,
N+, S–, s+; P1+; Lu(a–b+); K–, k+, Kp(a–b+); Le(a–b+);
Fy(a–b–); and Jk(a+b–). The Rh phenotype was deter-
mined to be C+, c+, DIII, E–, e+,V–,VS+, G+, hrB–, and
weakly hrS+. The probable genotype was CceS/DIIIce.
Anti-D, -Ce, and -hrB were identified in her serum.
Patient 2
The RBCs of the patient were typed as groupAB;M+,
N–,S+,s+;P1+;Lu(a–b+);K–,k+,Kp(a–b+),Js(b+);Le(a–
b+);Fy(a–b–);and Jk(a+b–). The Rh phenotype was C+,
Ce–, c+, DIII, E–, e+,V–,VS+, hrB–, and hrS+, probable
genotype CceS/DIIIce. Initially,weakly reacting anti-hrB
was identified in her serum. Toward the end of her
pregnancy, however, the patient developed a strongly
reacting anti-HrB. Weakly reacting anti-D, identified in
her serum in a previous pregnancy,was not detectable.
Discussion
We describe two patients with the probable Rh
genotype CceS/DIIIce and theVS+,hrB– phenotype;both
formed weakly reacting anti-hrB and weakly reacting
anti-D. Interestingly, with regard to Rh genotypes,Vege
and Westhoff5 have postulated that the loss of
expression of the hrB epitopes on RBCs may be a
dominant phenotype,as they report that the majority of
their hrB– donors were heterozygous, with some even
carrying conventional alleles. Individuals who are hrB–
often have variant D alleles.5 Patients who make anti-
hrB and have a DIII partial D phenotype are at risk of
making anti-D.3 Although there are no data available
regarding hemolytic transfusion reactions in association
with anti-hrB,1,2 the selection of hrB– RBCs has been
recommended for transfusion in cases of potent
anti-hrB.2 Once anti-hrB is identified, transfusion of hrB–
RBCs can be achieved by providing RBCs that are R2R2
(e–, hrB–).
In the case of Patient 1,weakly reacting anti-hrB,anti-
D, and anti-Ce were identified, and so r″r″ (cdE/cdE)
RBCs were selected for transfusion support. As far as we
are aware, there is only one case report of anti-hrB in
pregnancy (in abstract form).6 In that study, the
patient’s serum contained anti-hrB,weakly reacting anti-
D, and anti-Ce (serologic findings that are similar to
those seen in our Patient 1), and r″r″ RBCs were
provided for delivery, but the patient did not require
blood. The DAT on the RBCs from that infant’s cord
sample was positive,and anti-hrB+D+Ce was eluted from
the RBCs,with no evidence of HDN.6 In our Patient 1,
the DAT on the RBCs from the cord sample was
negative, with no evidence of HDN and the hospital
failed to investigate the infant’s hrB type.
In our Patient 2, anti-hrB broadened into anti-HrB
during the latter part of the pregnancy. Recent studies
from South Africa have confirmed that anti-HrB is a
clinically significant antibody that may cause HDN, and
transfusion of HrB– RBCs was recommended for patients
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with anti-HrB.4 Provision of suitable blood for Patient 2
imposed a special challenge, as HrB– RBCs cannot be
easily obtained from the existing UK donor population.
There were two options,either to import extremely rare
D– or DIII, HrB– RBCs from South Africa, or to provide
Rhnull RBCs. We were able to locate two units of Rhnull
RBCs through the UK Rare Donor Register. The patient
received these Rhnull RBCs, and the transfusions were
uneventful. Although the DAT on the infant’s RBCs was
positive, there was no clinical evidence of HDN. The
reference laboratory did not receive the infant’s sample
for HrB typing. A literature search confirms that, apart
from some publications in abstract form,3,4,6 there is not
much detailed clinical information available for either
anti-hrB or anti-HrB.4 The information obtainable from
abstracts is limited, and further case reports are
warranted to gain further knowledge concerning these
antibodies.
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